Key Insights

Highlights

Success Rate

77% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

12.5%

7 terminated out of 56 trials

Success Rate

76.7%

-9.9% vs benchmark

Late-Stage Pipeline

20%

11 trials in Phase 3/4

Results Transparency

30%

7 of 23 completed with results

Key Signals

7 with results77% success

Data Visualizations

Phase Distribution

30Total
Not Applicable (11)
Early P 1 (1)
P 1 (4)
P 2 (3)
P 3 (9)
P 4 (2)

Trial Status

Completed23
Recruiting10
Terminated7
Unknown6
Not Yet Recruiting3
Withdrawn2

Trial Success Rate

76.7%

Benchmark: 86.5%

Based on 23 completed trials

Clinical Trials (56)

Showing 20 of 20 trials
NCT00028080RecruitingPrimary

Evaluation, Treatment, and Follow-up of Patients With Lyme Disease

NCT01143558Early Phase 1CompletedPrimary

Searching for Persistence of Infection in Lyme Disease

NCT00001539RecruitingPrimary

A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations

NCT07561294Phase 2Active Not RecruitingPrimary

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)

NCT05975099Phase 1CompletedPrimary

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age

NCT07703787Not Yet Recruiting

Flow Cytometric Immune Monitoring of B. Afzelii-Specific T Lymphocytes

NCT07562087Phase 2Active Not RecruitingPrimary

A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure

NCT06397794RecruitingPrimary

Navigating Pregnancy and Parenthood With Lyme Disease

NCT06026969RecruitingPrimary

Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure

NCT05477524Phase 3CompletedPrimary

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

NCT05634811Phase 3CompletedPrimary

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

NCT07500506Phase 3RecruitingPrimary

A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

NCT05036707Phase 1Recruiting

Human Immune Response to Ixodes Scapularis Tick Bites

NCT06045416RecruitingPrimary

Borrelia B-cell Diagnostics

NCT04402086Recruiting

Rheumatology Patient Registry and Biorepository

NCT04038346Phase 3Terminated

Symptomatic Management of Lyme Arthritis

NCT00594997Not ApplicableCompletedPrimary

A School-Based Intervention to Reduce Lyme Disease

NCT06542289Not ApplicableNot Yet Recruiting

Safety and Effectiveness of the BlinkER System in Participants With Facial Nerve Palsy

NCT04148222WithdrawnPrimary

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Lyme Disease

NCT01793168Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Scroll to load more

Research Network

Activity Timeline